(51)CrEDTA colonic permeability and therapy response in patients with ulcerative colitis


Arslan G., Atasever T., Cindoruk M., Yildirim I.

NUCLEAR MEDICINE COMMUNICATIONS, vol.22, no.9, pp.997-1001, 2001 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 9
  • Publication Date: 2001
  • Doi Number: 10.1097/00006231-200109000-00009
  • Journal Name: NUCLEAR MEDICINE COMMUNICATIONS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.997-1001
  • Keywords: Cr-51 EDTA, intestinal permeability, ulcerative colitis, inflammatory bowel disease, INFLAMMATORY BOWEL-DISEASE, CR-51-LABELED ETHYLENEDIAMINETETRA-ACETATE, INCREASED INTESTINAL PERMEABILITY, CROHNS-DISEASE, CR-51 EDTA, LACTULOSE, RELATIVES, CALPROTECTIN, ABSORPTION, RHAMNOSE
  • Gazi University Affiliated: No

Abstract

Orally administered Cr-51-labelled ethylenediaminetetraacetic acid ((51)CrEDTA) has been used to evaluate intestinal permeability in inflammatory bowel disease, especially Crohn's disease. However, information about colonic permeability in ulcerative colitis (UC) is relatively scarce. The aim of this study was to investigate the urinary excretion of orally administered (51)CrEDTA, its relation to disease activity and its response to medical therapy in patients with UC.